Vaccines for colorectal cancer: an update.
Mostafa SarvizadehFaezeh GhasemiFatemeh TavakoliSara Sadat KhatamiEbrahim RaziHossein SharifiNousin Moussavi BioukiMohsen TaghizadehPublished in: Journal of cellular biochemistry (2018)
Colorectal cancer (CRC) is known as the third most common and fourth leading cancer associated death worldwide. The occurrence of metastasis has remained as a critical challenge in CRC, so that distant metastasis (mostly to the liver) has been manifested in about 20%-25% of patients. Several screening approaches have introduced for detecting CRC in different stages particularly in early stages. The standard treatments for CRC are surgery, chemotherapy and radiotherapy, in alone or combination. Immunotherapy is a set of novel approaches with the aim of remodeling the immune system battle with metastatic cancer cells, such as immunomodulatory monoclonal antibodies (immune checkpoint inhibitors), adoptive cell transfer (ACT) and cancer vaccine. Cancer vaccines are designed to trigger the intense response of immune system to tumor-specific antigens. In two last decades, introduction of new cancer vaccines and designing several clinical trials with vaccine therapy, have been taken into consideration in colon cancer patients. This review will describe the treatment approaches with the special attention to vaccines applied to treat colorectal cancer.
Keyphrases
- papillary thyroid
- clinical trial
- squamous cell
- end stage renal disease
- small cell lung cancer
- ejection fraction
- early stage
- minimally invasive
- risk assessment
- stem cells
- childhood cancer
- locally advanced
- lymph node metastasis
- lymph node
- dendritic cells
- working memory
- young adults
- bone marrow
- immune response
- atrial fibrillation
- patient reported outcomes